05 February 2021
Visiongain has just announced the publication of its brand new report Ophthalmic Drugs Market Report to 2030: Forecasts by Indication (Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs), by Type (Prescription Drugs, OTC Drugs), by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Ophthalmic Drugs Companies AND COVID-19 Recovery Scenarios.
Global Ophthalmic Drugs market was valued at US$XX million in 2020 and is projected to reach at a market value of US$XX million by 2030.
What new developments are taking place in the ophthalmic drug market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2030, assessing data, trends, opportunities and prospects there.
Includes EXCLUSIVE Covid-19 variations – not available anywhere else.
Our unique report provides tables, charts, and graphs not available anywhere else. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions.
Forecasts to 2030 and other analyses show you commercial prospects
Besides revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis), product profiles and commercial developments.
COVID-19 Impact on Ophthalmic Drugs Market
See revenue forecasts for the leading international markets
How will leading national markets perform to 2030? Our study forecasts ophthalmic drug revenues in national markets, including:
• North America
- United Kingdom
- Rest of Europe
• Asia Pacific
- South Korea
- Rest of Asia Pacific
• Latin America
- Rest of Latin America
• Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Leading companies and potential for market growth
Overall world revenue for ophthalmic drug market will reach $XX in 2021, our work forecasts. We predict strong revenue growth through to 2030. The ageing population in many of the world's largest markets will combine with a shift towards newer and more expensive lenses which will drive sales to 2030.
Our work analyses the key companies in the market. See Visiongain’s analysis of leading ophthalmic drug companies, including these:
• Santen Pharmaceutical Co.,
• Senju Pharmaceutical Company Ltd (Senju)
• Bausch Health Companies Inc.
• Akorn, Inc.
• Sun Pharmaceutical Industries Ltd.
• Aerie Pharmaceuticals Inc
A company profile gives you the following information where available:
• Historical revenues
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas and technologies.
The R&D pipeline for ophthalmic drugs is particularly strong, with faster and more precise drugs being in demand. Others, though not revolutionary are instead increase the efficiency of current therapies.
In this report you will discover key discussions on regulatory, technical, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market